

Special Issue

SARS-CoV-2: Vaccines in the Pandemic Era

Message from the Guest Editors

As of 17 November 2022, the COVID-19 pandemic has resulted in more than 636 million infections with over 6.6 million deaths (<https://coronavirus.jhu.edu/>). Since the pandemic, multiple SARS-CoV-2 vaccine platforms have been successfully developed for COVID-19, including messenger RNA (mRNA), inactivated virus, adenovirus vectors (Ad26.COVS.2 and ChAdOx1), and spike (S) protein subunit vaccine. These vaccines demonstrate high efficacy against SARS-CoV-2 and dramatical reduction in viral transmission, hospitalization, and deaths following two intramuscular injections. However, an increasing number of new SARS-CoV-2 variants of concern (VOCs) have emerged, including the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and recently dominant circulating Omicron variant. These emerging SARS-CoV-2 VOCs have significantly impaired the effectiveness of current SARS-CoV-2 vaccines. To achieve a more extensive understanding of recent scientific knowledge in SARS-CoV-2 vaccines, this Special issue focuses on SARS-CoV-2 vaccine development. We invite you contribute original research and reviews papers on SARS-CoV-2.

Guest Editors

Dr. Weihong Gu

Yale School of Medicine, Yale University, New Haven, CT 06510, USA

Dr. Yuexiu Zhang

Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/151111

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).